General Information
Enanta NASH EDP 305-101
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics and Efficacy Of EDP-305 In Subjects With Non-Alcoholic Steatohepatitis (NASH)
| Protocol | EDP 305-101 |
|---|---|
| Identifier | |
| UID | 30245e9f-cb06-4423-a2f3-9319c1bef5e1 |
| Status | Done - Archived |
| Phase | 2 |
| Category | NASH / Adult |
| Launch Year | 2018 |
| NCT Number | - |
| Created | 2018-05-01 16:28 |
| Last Updated | 2018-05-01 16:28 |
Description
No description provided.
Comment
CRI
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2019-03-08 | No |
| Enrollment Open | 2019-12-08 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2018-08-23 | No |
| PI Meeting Start | 2018-08-17 | No |
| PI Meeting End | 2018-08-17 | No |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2019-08-30 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Enanta Pharmaceuticals |
|---|---|
| Division | Enanta Pharmaceuticals |
| Team | Enanta Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ICON Clinical Research, LLC |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
